MaxCyte, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $33.0M | $38.6M | $41.3M | $44.3M | $33.9M | $26.2M | $21.6M |
| Cost of Revenue | $6.2M | $7.1M | $4.7M | $5.1M | $3.6M | $2.8M | $2.5M |
| Gross Profit | $26.8M | $31.5M | $36.5M | $39.2M | $30.2M | $23.4M | $19.1M |
| Gross Margin | 81.2% | 81.6% | 88.5% | 88.5% | 89.2% | 89.4% | 88.4% |
| Operating Expenses | |||||||
| Research & Development | $20.8M | $22.2M | $23.8M | $19.5M | $15.4M | $17.7M | $17.6M |
| SG&A Expense | $28.1M | $29.7M | $30.1M | $25.8M | $18.7M | $7.4M | $5.6M |
| Operating Income | $-51.9M | $-51.2M | $-48.3M | $-27.4M | $-18.2M | $-11.1M | $-12.4M |
| Operating Margin | -157.1% | -132.5% | -117.0% | -61.8% | -53.7% | -42.3% | -57.4% |
| Interest Expense | — | — | — | — | $5.4K | $21.7K | $51.9K |
| Pretax Income | $-44.6M | $-41.1M | $-37.9M | — | — | — | — |
| Income Tax Expense | — | — | — | — | $0 | $0 | $0 |
| Net Income | $-44.6M | $-41.1M | $-37.9M | $-23.6M | $-19.1M | $-11.8M | $-12.9M |
| Net Margin | -135.1% | -106.3% | -91.8% | -53.3% | -56.3% | -45.2% | -59.6% |
| EPS (Basic) | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 | $-0.17 | $-0.23 |
| EPS (Diluted) | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 | $-0.17 | $-0.23 |
| Shares Outstanding (Basic) | 106.4M | 104.8M | 103.3M | 101.7M | 90.6M | 69.5M | 56.4M |
| Shares Outstanding (Diluted) | 106.4M | 104.8M | 103.3M | 101.7M | 90.6M | 69.5M | 56.4M |
| Dividends Per Share | — | — | — | — | — | — | — |